---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-001472"
form_type: "8-K"
ticker: "NMRA"
cik: "0001885522"
company_name: "Neumora Therapeutics, Inc."
filed_at: "2026-01-05T23:59:59+00:00"
generated_at: "2026-05-16T11:43:15.719579+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# NMRA-511 Phase 1b shows clinically meaningful effect in AD agitation; navacaprant readout in Q2 2026

## Summary
- NMRA-511 Phase 1b: 15.7-point mean CMAI reduction, no somnolence/sedation; plan higher doses and Phase 2/3 in 2026
- Navacaprant KOASTAL-2 and -3 joint readout in Q2 2026; enrollment increased up to 25% beyond original target of 332
- NMRA-215 Phase 1 for obesity to initiate H1 2026; weight loss data expected around end of 2026
- Cash, cash equivalents and marketable securities support operations into Q3 2027; M4 PAM franchise update mid-2026

## SEC filing metadata
- accession: 0001193125-26-001472
- form_type: 8-K
- ticker: NMRA
- cik: 0001885522
- company_name: Neumora Therapeutics, Inc.
- filed_at: 2026-01-05T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1885522/000119312526001472/0001193125-26-001472-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1885522/000119312526001472/d33765d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-001472
- JSON: https://secwatch.observer/filing/0001193125-26-001472.json
- Plain text: https://secwatch.observer/filing/0001193125-26-001472.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.